Status:
COMPLETED
Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
TrygFonden, Denmark
Conditions:
Rapid Sequence Intubation
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Rapid sequence intubation is used, when there is an elevated risk of aspiration to the lungs of stomach content. It is typically used in acute settings that require acute surgery or in prehospital set...
Eligibility Criteria
Inclusion
- Elective surgical patients with a planned rapid sequence induction of anaesthesia.
- Informed consent.
- Legally competent.
- Be able to understand Danish and be able to read the given information in Danish.
- Females can only participate if they have reached menopause, have had hysterectomy performed, use a coil as birthcontrol, or if they are sterilized.
Exclusion
- Presence of kidney disease, defined as S-creatinine \>0,200 mmol/L.
- Known lung or heart disease, defined as NYHA-class \>2 or CCS-class \>2.
- Known allergic reactions to Rocuronium, Suxamethon, Propofol or Sugammadex.
- Contraindications to Suxamethon. Including raised P-potassium (\>5,0 mmol/L), untreated glaucoma, neuromuscular disorders or disposition to malignant hyperthermia.
- Body mass index of \>35 kg/m2.
- Pregnant.
- Breastfeeding.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00953550
Start Date
September 1 2009
End Date
February 1 2011
Last Update
March 2 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100
2
Herlev Hospital
Herlev, Denmark, 2730